IBT specializes in delivering top-notch reagents tailored for research and development purposes.
An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in
IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million to advance the development
4 November 2019 INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019 Integrated
CARB-X global partnership headed toward developing an innovative vaccine against potentially deadly Staphylococcus aureus bacteria that could be a “game
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the
Subscribe to the IBT Bioservices Tech Talk list and receive periodic updates on industry news and IBT Bioservices products and services.